Cellular and molecular pharmacology of antiestrogen action and resistance - PubMed (original) (raw)
Affiliations
- PMID: 11171938
Review
Cellular and molecular pharmacology of antiestrogen action and resistance
R Clarke et al. Pharmacol Rev. 2001 Mar.
Abstract
Antiestrogen therapy remains one of the most widely used and effective treatments for the management of endocrine responsive breast cancers. This reflects the ability of antiestrogens to compete with estrogens for binding to estrogen receptors. Whereas response rates of up to 70% are reported in patients with tumors expressing estrogen and progesterone receptors, most responsive tumors will eventually acquire resistance. The most important factor in de novo resistance is lack of expression of these receptors. However, the mechanisms driving resistance in tumors that express estrogen and/or progesterone receptors are unclear. A tamoxifen-stimulated phenotype has been described, but seems to occur only in a minority of patients. Most tumors (>80%) may become resistant through other, less well defined, resistance mechanisms. These may be multifactorial, including changes in immunity, host endocrinology, and drug pharmacokinetics. Significant changes within the tumor cells may also occur, including alterations in the ratio of the estrogen receptor alpha:beta forms and/or other changes in estrogen receptor-driven transcription complex function. These may lead to perturbations in the gene network signaling downstream of estrogen receptors. Cells may also alter paracrine and autocrine growth factor interactions, potentially producing a ligand-independent activation of estrogen receptors by mitogen-activated protein kinases. Antiestrogens can affect the function of intracellular proteins and signaling that may, or may not, involve estrogen receptor-mediated events. These include changes in oxidative stress responses, specific protein kinase C isoform activation, calmodulin function, and cell membrane structure/function.
Similar articles
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Clarke R, et al. Oncogene. 2003 Oct 20;22(47):7316-39. doi: 10.1038/sj.onc.1206937. Oncogene. 2003. PMID: 14576841 Review. - Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC. Dardes RC, et al. Clin Cancer Res. 2002 Jun;8(6):1995-2001. Clin Cancer Res. 2002. PMID: 12060645 - Antiestrogen pharmacology and mechanism of action.
Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K. Katzenellenbogen BS, et al. J Steroid Biochem. 1983 Jul;19(1A):59-68. J Steroid Biochem. 1983. PMID: 6887873 - Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H, Arteaga CL. Kurokawa H, et al. Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916237 Review.
Cited by
- Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.
Weng L, Ziliak D, Im HK, Gamazon ER, Philips S, Nguyen AT, Desta Z, Skaar TC, Flockhart DA, Huang RS; Consortium on Breast Cancer Pharmacogenomics (COBRA). Weng L, et al. Ann Oncol. 2013 Jul;24(7):1867-1873. doi: 10.1093/annonc/mdt125. Epub 2013 Mar 18. Ann Oncol. 2013. PMID: 23508821 Free PMC article. - A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.
Bastian A, Thorpe JE, Disch BC, Bailey-Downs LC, Gangjee A, Devambatla RK, Henthorn J, Humphries KM, Vadvalkar SS, Ihnat MA. Bastian A, et al. J Pharmacol Exp Ther. 2015 May;353(2):392-404. doi: 10.1124/jpet.114.220335. Epub 2015 Feb 26. J Pharmacol Exp Ther. 2015. PMID: 25720766 Free PMC article. - Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.
Baumgarten SC, Frasor J. Baumgarten SC, et al. Mol Endocrinol. 2012 Mar;26(3):360-71. doi: 10.1210/me.2011-1302. Epub 2012 Feb 2. Mol Endocrinol. 2012. PMID: 22301780 Free PMC article. Review. - Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate.
Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, Baumann WT, Tyson JJ, Xuan J, Wang Y, Wärri A, Shajahan AN. Clarke R, et al. Cancer Res. 2012 Mar 15;72(6):1321-31. doi: 10.1158/0008-5472.CAN-11-3213. Cancer Res. 2012. PMID: 22422988 Free PMC article. Review. - CAPER, a novel regulator of human breast cancer progression.
Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF. Mercier I, et al. Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17. Cell Cycle. 2014. PMID: 24621503 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources